AI-generated analysis
Vance Street Capital’s acquisition of Excel Scientific, a leading provider of consumable films and foils for life science applications, strategically positions Vance Street to capitalize on the growing demand for laboratory consumables in the biotech and pharmaceutical industries. Excel’s proprietary sealing solutions protect testing samples from contamination and degradation during critical phases such as storage and analysis, making it an essential supplier in high-growth end markets like genomics research and clinical diagnostics.
The transaction represents Vance Street Capital’s second platform investment out of its third fund, highlighting a continued focus on the life sciences sector. While financial details remain undisclosed, the deal likely reflects a valuation multiple that aligns with Excel’s robust growth trajectory and market leadership position. Debt financing was provided by BMO Sponsor Finance, underscoring the confidence in Excel’s strong cash flows and future growth prospects.
This acquisition reshapes competitive dynamics within the laboratory consumables segment. By integrating its existing industry expertise from prior investments like Axygen Biosciences, Vance Street aims to drive further innovation and market penetration for Excel’s products. The deal also strengthens competition against larger players such as Thermo Fisher Scientific and Eppendorf, which are active in similar product categories.
Post-close, key risks include potential disruptions in supply chains due to ongoing global health concerns and the need to maintain high levels of customer satisfaction amidst rapid industry growth. Integration challenges will revolve around leveraging Vance Street’s network to expand distribution channels while preserving Excel’s culture of innovation under new ownership. With a strategic vision for market expansion and product development, Excel is poised for significant growth in its core markets as well as emerging applications within life sciences research.
Vance Street Capital LLC has acquired Excel Scientific, Inc., a provider of consumable films and foils used in life science applications, effective as of January 12, 2021. The terms of the deal were not disclosed.
| Acquirer: | Vance Street Capital LLC |
| Target: | Excel Scientific, Inc. |
| Deal value: | Undisclosed |
| Type: | Acquisition |
| Closing date: | January 12, 2021 |
| Buy-side advisors: | RA Capital Advisors |
| Sell-side advisors: | Not disclosed |
| Legal (buy): | Vedder Price |
| Legal (sell): | Squire Patton Boggs |
The acquisition is intended to support Excel Scientific's next phase of growth and leverage Vance Street Capital’s previous experience in the life sciences sector.
Deal Rationale
Vance Street Capital aims to accelerate the growth trajectory of Excel Scientific by drawing on its extensive network within the healthcare industry. The strategic partnership will allow for enhanced innovation and commercialization efforts, positioning Excel Scientific as a key player in the provision of consumable films and foils.
Financial Context
The deal's terms remain undisclosed but are expected to be structured in a way that complements Vance Street Capital’s investment strategy. The company has previously invested in various healthcare companies with a focus on providing operational support and strategic guidance.